Appendix Table C32. Clinical outcomes (outcomespart B), ACEI plus CCB versus ACEI monotherapy or CCB monotherapy trial

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Stroke, Nonfatal,****n/N (%)** | **Stroke, Fatal,****n/N (%)** | **CHF, Any,****n/N (%)** | **CHF Hospitalization (A) or Death (B),****n/N (%)** | **Composite Vascular Outcome,****n/N (%)** |
| **ACEI+ CCB** | **ACEI** | **CCB** | **ACEI+ CCB** | **ACEI** | **CCB** | **ACEI+ CCB** | **ACEI** | **CCB** | **ACEI+ CCB** | **ACEI** | **CCB** | **ACEI+ CCB** | **ACEI** | **CCB** |
| Fogari, 200224  | 1/104 (1.0) | 2/102 (1.9) | 2/103 (1.9) | 0/104  | 1/102 (1.0) | 0/103  |  |  |  |  |  |  |  |  |  |

ACEI = angiotensin converting enzyme; CCB = calcium channel blocker; CHF = congestive heart failure
\*Other no-fatal cardiovascular events (not defined): ACEI+CCB: 1/104 (1.0%), ACEI: 1/102 (1.0%), CCB: 2/103 (1.9%)